RT Journal Article
SR Electronic
T1 Gemcitabine and Oral Vinorelbine as Salvage Treatment in Patients with Advanced Anthracycline- and Taxane-pretreated Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2989
OP 2992
VO 27
IS 4C
A1 A. ARDAVANIS
A1 P. KOUNTOURAKIS
A1 S. MALIOU
A1 M. VASSILAKOPOULOU
A1 S. BASIOUKAS
A1 F. KYRIAKOU
A1 S. KOUMNA
A1 G. RIGATOS
YR 2007
UL http://ar.iiarjournals.org/content/27/4C/2989.abstract
AB Background: Despite progress achieved with new chemotherapeutic and endocrine agents, advanced breast cancer (ABC) remains a disease with poor prognosis. We sought to determine the efficacy of gemcitabine (GC) and oral vinorelbine (VB) in heavily preatreated ABC. Patients and Methods: Patients previously treated with anthracyclines and taxanes in the metastatic setting with progressive disease were eligible. Treatment consisted of VB (60 mg/m2, orally) and GC (1000 mg/m2, intravenous infusion), every two weeks of a 28-day cycle. Results: Thirty-one patients with ABC were enrolled. Toxicity was acceptable, mainly haematological. Three and 8 patients achieved a complete (9.6%) and partial (25.8%) response, respectively; ten patients (32.2%) had stable disease. Median time-to-progression was 5.3 months, while in responders 8.6 months. Median overall survival was 14 months. Conclusion: Oral VB and GC is an active and well-tolerated combination in anthracycline/taxane-pretreated ABC, representing an interesting option in this poor prognosis group of patients.